KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Income towards Parent Company (2016 - 2025)

CRISPR Therapeutics AG's Income towards Parent Company history spans 11 years, with the latest figure at -$129.7 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 135.43% year-over-year to -$129.7 million; the TTM value through Dec 2025 reached -$580.7 million, down 1663.08%, while the annual FY2025 figure was -$580.7 million, 1662.62% down from the prior year.
  • Income towards Parent Company for Q4 2025 was -$129.7 million at CRISPR Therapeutics AG, down from -$106.4 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $759.2 million in Q2 2021 and bottomed at -$208.6 million in Q2 2025.
  • The 5-year median for Income towards Parent Company is -$114.9 million (2021), against an average of -$39.5 million.
  • The largest annual shift saw Income towards Parent Company skyrocketed 1053.13% in 2021 before it crashed 135.43% in 2025.
  • A 5-year view of Income towards Parent Company shows it stood at -$139.5 million in 2021, then grew by 19.11% to -$112.9 million in 2022, then surged by 339.24% to $270.0 million in 2023, then skyrocketed by 35.6% to $366.1 million in 2024, then plummeted by 135.43% to -$129.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Income towards Parent Company are -$129.7 million (Q4 2025), -$106.4 million (Q3 2025), and -$208.6 million (Q2 2025).